Progress of targeting transforming growth factor-β1 small interfering RNA in liver fibrosis / 中国医学科学杂志(英文版)
Chinese Medical Sciences Journal
; (4): 231-235, 2014.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-242863
Responsible library:
WPRO
ABSTRACT
Liver fibrosis is a common pathological consequence of a variety of chronic stimuli, including viral, autoimmune, drug-induced, cholestatic and metabolic diseases. Fibrosis is driven by a dynamic process involving increased synthesis of matrix components and a failure of physiological mechanisms of matrix turnover. Activation of hepatic stellate cells (HSCs) remains a central event in fibrosis. HSCs are the main source of extracellular matrix (ECM). Transforming growth factor-beta (TGF-Β), which is the fibrogenic master cytokine, can induce the activation of HSCs to produce a large amount of ECM, and is capable of inducing apoptosis of liver cells. RNA interference (RNAi) is a novel gene disruption technology. Studies have shown that small interfering RNA (siRNA) targeting TGF-Β1 may inhibit the activation and proliferation of HSCs, suppress ECM synthesis and block liver fibrosis. TGF-Β1 siRNA-mediated gene silencing therapy provides a new avenue for liver fibrosis. This review summarizes recent progresses in research on HSCs, TGF-Β1 and TGF-Β1 siRNA in liver fibrosis.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
RNA, Small Interfering
/
Transforming Growth Factor beta1
/
Genetics
/
Liver Cirrhosis
Language:
English
Journal:
Chinese Medical Sciences Journal
Year:
2014
Document type:
Article